Mineo T C, Ambrogi V, Baldi A, Rabitti C, Bollero P, Vincenzi B, Tonini G
Department of Thoracic Surgery, Policlinic Tor Vergata University, 00133 Rome, Italy.
J Clin Pathol. 2004 Jun;57(6):591-7. doi: 10.1136/jcp.2003.013508.
To evaluate the prognostic impact of tumour angiogenesis assessed by vascular endothelial growth factor (VEGF), microvessel density (MVD), and tumour vessel invasion in patients who had undergone radical resection for stage IB-IIA non-small cell lung cancer (NSCLC).
Fifty one patients (42 men, nine women; mean age, 62.3 years; SD, 6.9) undergoing complete surgical resection (35 lobectomy, 16 pneumonectomy) of pathological stage IB (n = 43) and IIA (n = 8) NSCLC were evaluated retrospectively. No patient underwent postoperative chemotherapy or neoadjuvant treatment. Tumour specimens were stained for VEGF and specific MVD markers: CD31, CD34, and CD105.
VEGF expression significantly correlated with high CD105 expression (p < 0.0001) and tumour vessel invasion (p = 0.04). Univariate analysis showed that those patients with VEGF overexpression (p = 0.0029), high MVD by CD34 (p = 0.0081), high MVD by CD105 (p = 0.0261), and tumour vessel invasion (p = 0.0245) have a shorter overall survival. Furthermore, multivariate Cox regression analysis showed that MVD by CD34 (p = 0.007), tumour vessel invasion (p = 0.024), and VEGF expression (p = 0.042) were significant predictive factors for overall survival. Finally, the presence of both risk factors, tumour vessel invasion and MVD by CD34, was highly predictive of poor outcome (odds ratio, 3.4; 95% confidence interval, 1.7 to 6.5; p = 0.0002).
High MVD by CD34 and tumour vessel invasion are more closely related to poor survival than the other neoangiogenetic factors in stage IB-IIA NSCLC. This may be because these factors are more closely related to the metastatic process.
评估血管内皮生长因子(VEGF)、微血管密度(MVD)和肿瘤血管浸润对IB-IIA期非小细胞肺癌(NSCLC)患者行根治性切除术后的预后影响。
回顾性评估51例接受病理分期为IB期(n = 43)和IIA期(n = 8)NSCLC完整手术切除(35例肺叶切除术,16例全肺切除术)的患者(42例男性,9例女性;平均年龄62.3岁;标准差6.9)。所有患者均未接受术后化疗或新辅助治疗。肿瘤标本进行VEGF和特定MVD标志物染色:CD31、CD34和CD105。
VEGF表达与高CD105表达(p < 0.0001)和肿瘤血管浸润(p = 0.04)显著相关。单因素分析显示,VEGF过表达(p = 0.0029)、CD34高MVD(p = 0.0081)、CD105高MVD(p = 0.0261)和肿瘤血管浸润(p = 0.0245)的患者总生存期较短。此外,多因素Cox回归分析显示,CD34的MVD(p = 0.007)、肿瘤血管浸润(p = 0.024)和VEGF表达(p = 0.042)是总生存期的显著预测因素。最后,肿瘤血管浸润和CD34的MVD这两个危险因素的存在高度预测不良预后(比值比,3.4;95%置信区间,1.7至6.5;p = 0.0002)。
在IB-IIA期NSCLC中,CD34高MVD和肿瘤血管浸润比其他新生血管生成因素与较差的生存率更密切相关。这可能是因为这些因素与转移过程更密切相关。